Literature DB >> 3986776

Carbamoylation of glutathione reductase and changes in cellular and chromosome morphology in a rat cell line resistant to nitrogen mustards but collaterally sensitive to nitrosoureas.

K D Tew, G Kyle, A Johnson, A L Wang.   

Abstract

A Walker 256 rat carcinoma cell line (WR) with acquired resistance to nitrogen mustards has been found to lack cross-resistance to nitrosoureas. Although total cellular glutathione pools were similar in the parent (WS) and resistant cell lines (WS, 2.5 X 10(-6); WR, 2.0 X 10(-6) mol/mg protein), glutathione reductase activity was 3.98 in WR compared to 8.67 nmol reduced nicotinamide adenine dinucleotide phosphate oxidized per microgram protein per min in WS cells. Treatment of cells with a carbamoylating nitrosourea, N,N'-bis(trans-4-hydroxycyclohexyl)-N'-nitrosourea, produced a dose-dependent inhibition of glutathione reductase and depletion of thiols in both cell lines. The drug caused no direct DNA strand breakage, but a differential mitotic spindle-chromosome stain showed that spindle formation was inhibited in WR cells at N,N'-bis(trans-4-hydroxycyclohexyl)-N'-nitrosourea concentrations of greater than 50 microM. In WS cells, mitotic figures were still visible at 100 microM. Chromosomal damage was expressed in both cell lines at concentrations of 25 microM. The number and extent of these aberrations were greater in WR than WS. Observed karyotypic abnormalities included polyploidy, chromosome decondensation, and endoreduplication. In interphase cells, transmission electron microscopy showed that the most prevalent drug-induced lesions included (a) disappearance of plasma membrane filopodia, (b) appearance of membrane blebbing, and (c) development of irregular crescent-shaped nuclei. These morphological and cytogenetic changes correlate with cytotoxic responses of these cell lines to N,N'-bis(trans-4-hydroxycyclohexyl)-N'-nitrosourea and would be consistent with drug-induced inhibition of glutathione reductase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3986776

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Development of alkylating agent-resistant human tumor cell lines.

Authors:  B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Influence of pH on the modification of thiols by carbamoylating agents and effects on glutathione levels in normal and neoplastic cells.

Authors:  J J Hu; M J Dimaira; K A Zirvi; G Dikdan; M A Lea
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Enhancement of anthracycline and alkylator cytotoxicity by ethacrynic acid in primary cultures of human tissues.

Authors:  R A Nagourney; J C Messenger; D H Kern; L M Weisenthal
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  The effect of a novel taurine nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl)ethyl]-1-nitrosour ea (TCNU) on cytotoxicity, DNA crosslinking and glutathione reductase in lung carcinoma cell lines.

Authors:  K D Tew; S W Dean; N W Gibson
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Severe depletion of cellular thiols and glutathione-related enzymes of a carmustine-resistant L1210 strain associates with collateral sensitivity to cyclophosphamide.

Authors:  E Institoris; L Tretter; D Gaál
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.

Authors:  L A Speicher; V R Sheridan; A K Godwin; K D Tew
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

7.  Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells.

Authors:  Sangeetha Sukumari-Ramesh; Niyathi Prasad; Cargill H Alleyne; John R Vender; Krishnan M Dhandapani
Journal:  BMC Cancer       Date:  2015-03-13       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.